SI1592401T1 - Postopek za modificiranje zdravilne kristalne oblike mikofenola natrijeve soli - Google Patents

Postopek za modificiranje zdravilne kristalne oblike mikofenola natrijeve soli

Info

Publication number
SI1592401T1
SI1592401T1 SI200431859T SI200431859T SI1592401T1 SI 1592401 T1 SI1592401 T1 SI 1592401T1 SI 200431859 T SI200431859 T SI 200431859T SI 200431859 T SI200431859 T SI 200431859T SI 1592401 T1 SI1592401 T1 SI 1592401T1
Authority
SI
Slovenia
Prior art keywords
sodium salt
crystal formation
mycophenolate sodium
drug crystal
modifying drug
Prior art date
Application number
SI200431859T
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1592401(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1592401T1 publication Critical patent/SI1592401T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Furan Compounds (AREA)
SI200431859T 2003-01-20 2004-01-19 Postopek za modificiranje zdravilne kristalne oblike mikofenola natrijeve soli SI1592401T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds
PCT/EP2004/000354 WO2004064806A2 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation
EP04703158A EP1592401B1 (en) 2003-01-20 2004-01-19 Process for modifying drug crystal formation of mycophenolate sodium salt

Publications (1)

Publication Number Publication Date
SI1592401T1 true SI1592401T1 (sl) 2012-05-31

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431859T SI1592401T1 (sl) 2003-01-20 2004-01-19 Postopek za modificiranje zdravilne kristalne oblike mikofenola natrijeve soli

Country Status (32)

Country Link
US (3) US20060122265A1 (sl)
EP (2) EP1592401B1 (sl)
JP (1) JP4549976B2 (sl)
KR (5) KR20090115821A (sl)
CN (2) CN100595199C (sl)
AR (2) AR043343A1 (sl)
AT (1) ATE546132T1 (sl)
AU (1) AU2004206731B2 (sl)
BR (1) BRPI0406827A (sl)
CA (2) CA2509796C (sl)
CL (1) CL2004000073A1 (sl)
CO (1) CO5580738A2 (sl)
CY (1) CY1112772T1 (sl)
DK (1) DK1592401T3 (sl)
EC (1) ECSP055918A (sl)
ES (1) ES2382035T3 (sl)
GB (1) GB0301259D0 (sl)
HK (1) HK1084874A1 (sl)
IL (1) IL169484A (sl)
MX (1) MXPA05007691A (sl)
MY (1) MY148297A (sl)
NO (1) NO20053846L (sl)
NZ (1) NZ541073A (sl)
PE (2) PE20110276A1 (sl)
PL (2) PL213192B1 (sl)
PT (1) PT1592401E (sl)
RU (1) RU2388757C2 (sl)
SG (1) SG155046A1 (sl)
SI (1) SI1592401T1 (sl)
TW (1) TWI325785B (sl)
WO (1) WO2004064806A2 (sl)
ZA (1) ZA200504442B (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
CA2553881A1 (en) 2004-04-26 2005-11-10 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for preparation of mycophenolic acid and ester derivatives thereof
EP1740563A2 (en) 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
EP1699773A2 (en) 2004-07-20 2006-09-13 Ceva Gyogyszergyar R Szv Nytarsasag Processes for preparation of crystalline mycophenolate sodium
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
PT2349220E (pt) * 2008-10-09 2012-10-11 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Utilização de solventes orgânicos na granulação húmida de moxifloxacina
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
PL2451797T3 (pl) 2009-07-10 2013-08-30 Janssen Pharmaceutica Nv Proces krystalizacji dla 1-(ß-D-glukopiranozylo)-4-metylo-3-[5-(4-fluorofenylo)-2-tienylometylo]benzenu
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
CN103221391B (zh) 2010-01-27 2018-07-06 艾尼纳制药公司 (R)-2-(7-(4-环戊基-3-(三氟甲基)苄基氧基)-1,2,3,4-四氢环戊二烯并[b]吲哚-3-基)乙酸及其盐的制备方法
BR112012028857B1 (pt) 2010-05-11 2021-02-09 Janssen Pharmaceutica Nv Composições farmacêuticas administráveis por via oral que compreendem derivados de 1- (beta-d glucopiranosil)-2-tienil-metilbenzeno como inibidores de sglt
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103596944B (zh) 2011-04-13 2017-02-22 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
US10301262B2 (en) 2015-06-22 2019-05-28 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2017108752A1 (en) * 2015-12-21 2017-06-29 Janssen Pharmaceutica Nv Crystallization procedure for obtaining canagliflozin hemihydrate crystals
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MA47503A (fr) 2017-02-16 2021-04-21 Arena Pharm Inc Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2023234158A1 (ja) * 2022-05-31 2023-12-07 本州化学工業株式会社 ４，４'－ビス（１，１－ビス（４－ヒドロキシ－３－メチルフェニル）エチル）ビフェニルの結晶及び、その製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
ATE173475T1 (de) 1993-09-15 1998-12-15 Syntex Inc Kristallines, wasserfreies mofetilmycophenolat und zubereitungen zu deren intravenösen anwendung
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PL213192B1 (pl) 2013-01-31
PE20110276A1 (es) 2011-05-27
NZ541073A (en) 2008-12-24
TW200505505A (en) 2005-02-16
ES2382035T3 (es) 2012-06-04
MY148297A (en) 2013-03-29
CA2509796C (en) 2010-09-14
JP2006515016A (ja) 2006-05-18
AU2004206731B2 (en) 2008-03-20
CL2004000073A1 (es) 2005-01-14
EP2308471A1 (en) 2011-04-13
MXPA05007691A (es) 2005-09-30
KR20090115898A (ko) 2009-11-09
EP1592401B1 (en) 2012-02-22
ZA200504442B (en) 2006-02-22
KR20070087181A (ko) 2007-08-27
AU2004206731A8 (en) 2004-08-05
KR20100120321A (ko) 2010-11-15
CY1112772T1 (el) 2016-02-10
SG155046A1 (en) 2009-09-30
RU2005126328A (ru) 2006-07-27
PL376525A1 (pl) 2006-01-09
US20060122265A1 (en) 2006-06-08
TWI325785B (en) 2010-06-11
US20110288313A1 (en) 2011-11-24
DK1592401T3 (da) 2012-05-21
ATE546132T1 (de) 2012-03-15
EP1592401A2 (en) 2005-11-09
CO5580738A2 (es) 2005-11-30
IL169484A0 (en) 2007-07-04
JP4549976B2 (ja) 2010-09-22
CA2509796A1 (en) 2004-08-05
CN1738605A (zh) 2006-02-22
BRPI0406827A (pt) 2005-12-27
US8008511B2 (en) 2011-08-30
WO2004064806A3 (en) 2004-10-28
GB0301259D0 (en) 2003-02-19
PL393385A1 (pl) 2011-03-14
RU2388757C2 (ru) 2010-05-10
CN100595199C (zh) 2010-03-24
KR101129105B1 (ko) 2012-04-12
AU2004206731A1 (en) 2004-08-05
HK1084874A1 (en) 2006-08-11
PE20040826A1 (es) 2004-12-23
KR20050096940A (ko) 2005-10-06
US20090209639A1 (en) 2009-08-20
AR043343A1 (es) 2005-07-27
NO20053846L (no) 2005-08-16
CN101333201A (zh) 2008-12-31
AR103711A2 (es) 2017-05-31
KR20090115821A (ko) 2009-11-06
PT1592401E (pt) 2012-05-10
IL169484A (en) 2016-03-31
KR100855149B1 (ko) 2008-08-28
WO2004064806A2 (en) 2004-08-05
US8124795B2 (en) 2012-02-28
CA2706900A1 (en) 2004-08-05
ECSP055918A (es) 2005-11-22

Similar Documents

Publication Publication Date Title
HK1084874A1 (en) Process for modifying drug crystal formation of mycophenolate sodium salt
GB2395946B (en) Method for the production of sodium chloride from seawater
ZA200507297B (en) Process for preparation of phenethylamine derivatives
HK1095817A1 (en) Method for the production of amino crotonyl compounds
HK1082735A1 (en) Process for preparing the calcium salt of rosuvastatin
PT3281939T (pt) Combinação contendo um cristal estável de compostos de 4-oxoquinolina
HK1079532A1 (en) Process for selective production of aryl 5-thio-beta-d-aldohexopyranosides
IL190137A0 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
IL216449A0 (en) Process for the preparation of tetrazole derivatives
IL170887A (en) Process for the preparation of 2 - cyanopyrolidines converted at position n
IL174592A0 (en) Processes for the preparation of a polymorph of fluvastantin sodium
HUP0402391A3 (en) Crystalline sodium salt of telmisartan, process for its production and pharmaceutical compositions containing it
EP1676835A4 (en) METHOD FOR PRODUCING TRIARYL SULPHONIUM SALTS
EP1712524A4 (en) AQUEOUS CHROMIUM SALT SOLUTION AND MANUFACTURING METHOD THEREFOR
AU2003237598A8 (en) Process for the preparation of highly pure rabeprazole sodium salt
EP1614774A4 (en) PROCESS FOR PRODUCING A SINGLE CRYSTAL
EP1679392A4 (en) PROCESS FOR PRODUCING MONOCRYSTAL
SI1551414T1 (sl) Postopek za pripravo kristalne oblike I olanzapina
EP1632476A4 (en) ACIDIC ACID SALT OF A CARBAZUCKERAMINE DERIVATIVE
HUP0402634A2 (en) Process for producing meloxicam and meloxicam potassium salt of high purity
GB2406565B (en) Method for refining aqueous nickel chloride solution
IL149771A0 (en) Process for preparation of torsemide
EP1484314A4 (en) METHOD FOR PRODUCING OPTICALLY ACTIVE BETA PHENYL ALANINE DERIVATIVES
GEU20041064U (en) Method for production of Matsoni
HU0301663D0 (en) Process for producing of coffee-cream